Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant
{{output}}
Aim: To assess the 5-year healthcare resource utilization (HRU) and direct payer costs following allogeneic hematopoietic stem cell transplants (HSCTs) in acute lymphoblastic leukemia pediatric patients using data from two large ... ...
